David Ashley

Overview:

Dr. Ashley's primary research focus is laboratory based, investigating the role of immunotherapy as a novel approach to the treatment of tumors of the central nervous system (CNS). Since beginning his appointment at the faculty level at Duke in August of 1995 his activities have centered on two main areas of investigation. The first involves both in vivo and in vitro studies of the use of molecular therapeutics to target a CNS tumor associated antigen. The second area of interest comprises a detailed analysis of the role of TGF beta, a protein messenger produced by tumors of the CNS, both in the pathogenesis of disease and as a possible target for immunotherapy.

In addition to his laboratory role Dr. Ashley is involved in the design and application of a variety of clinical research protocols in the treatment of children with malignant brain tumors.

Positions:

Rory David Deutsch Distinguished Professor of Neuro-Oncology

Neurosurgery
School of Medicine

Professor of Neurosurgery

Neurosurgery
School of Medicine

Professor of Medicine

Medicine, Medical Oncology
School of Medicine

Professor in Pediatrics

Pediatrics, Neurology
School of Medicine

Professor in Pathology

Pathology
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

F.R.A.C.P. 1993

Royal Australian College of Physicians

M.B.B.S. 1994

University of Melbourne (Australia)

Ph.D. 1998

University of Melbourne (Australia)

Grants:

LGG-14C03: A Phase III study comparing two carboplatin containing regimens for children and young adults with previously untreated low grade glioma

Administered By
Duke Cancer Institute
Awarded By
Ann & Robert H. Lurie Children's Hospital of Chicago
Role
Principal Investigator
Start Date
End Date

A Randomized, Multicenter, Phase 2 Study of PVSRIPO alone or in combination with Lomustine

Administered By
Duke Cancer Institute
Role
Principal Investigator
Start Date
End Date

Recombinant Attenuated Poliovirus Immunization Vectors Targeting H3.3(K27M) in DIPG

Administered By
Neurosurgery, Neuro-Oncology Clinical Research
Role
Principal Investigator
Start Date
End Date

SJMB12: A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma

Administered By
Pediatrics, Hematology-Oncology
Awarded By
St. Jude Children's Research Hospital
Role
Principal Investigator
Start Date
End Date

Head Start 4

Administered By
Duke Cancer Institute
Role
Principal Investigator
Start Date
End Date

Publications:

Brain immunology and immunotherapy in brain tumours.

Gliomas, the most common malignant primary brain tumours, remain universally lethal. Yet, seminal discoveries in the past 5 years have clarified the anatomy, genetics and function of the immune system within the central nervous system (CNS) and altered the paradigm for successful immunotherapy. The impact of standard therapies on the response to immunotherapy is now better understood, as well. This new knowledge has implications for a broad range of tumours that develop within the CNS. Nevertheless, the requirements for successful therapy remain effective delivery and target specificity, while the dramatic heterogeneity of malignant gliomas at the genetic and immunological levels remains a profound challenge.
MLA Citation
Sampson, John H., et al. “Brain immunology and immunotherapy in brain tumours..” Nat Rev Cancer, vol. 20, no. 1, Jan. 2020, pp. 12–25. Pubmed, doi:10.1038/s41568-019-0224-7.
URI
https://scholars.duke.edu/individual/pub1423063
PMID
31806885
Source
pubmed
Published In
Nat Rev Cancer
Volume
20
Published Date
Start Page
12
End Page
25
DOI
10.1038/s41568-019-0224-7

The role of chemotherapy in the treatment of central neurocytoma.

Aim: Central neurocytoma (CN) is a rare WHO grade II central nervous system (CNS) tumor. This is an update on chemotherapeutic agents used in its treatment. Patients & methods: An institutional review board-approved, chart review of patients seen at our institution resulted in a single case treated with chemotherapy and is herein included. We proceeded with a comprehensive literature review. Results: We identified 18 citations, representing 39 cases of adult and pediatric CN treated with chemotherapy. With the addition of our single case, the total number of recurrent CN patients treated with temozolomide (TMZ) is nine. Conclusion: There exists marked heterogeneity in chemotherapy used to treat CN. TMZ is incorporated into treatment regimens in the setting of tumor recurrence: its role merits further study.
MLA Citation
Johnson, Margaret O., et al. “The role of chemotherapy in the treatment of central neurocytoma..” Cns Oncol, vol. 8, no. 3, Nov. 2019. Pubmed, doi:10.2217/cns-2019-0012.
URI
https://scholars.duke.edu/individual/pub1417984
PMID
31686534
Source
pubmed
Published In
Cns Oncology
Volume
8
Published Date
Start Page
CNS41
DOI
10.2217/cns-2019-0012

Outcomes Following Adjuvant Radiation Therapy in Elderly Patients with Glioblastoma: A Retrospective Single Institution Analysis

Authors
Lee, JWC; Johnson, MO; Kirkpatrick, JP; McSherry, F; Herndon, J; Lipp, ES; Desjardins, A; Randazzo, D; Friedman, HS; Ashley, DM; Peters, KB
MLA Citation
Lee, J. W. C., et al. “Outcomes Following Adjuvant Radiation Therapy in Elderly Patients with Glioblastoma: A Retrospective Single Institution Analysis.” International Journal of Radiation Oncology*Biology*Physics, vol. 105, no. 1, Elsevier BV, 2019, pp. E102–E102. Crossref, doi:10.1016/j.ijrobp.2019.06.2296.
URI
https://scholars.duke.edu/individual/pub1414293
Source
crossref
Published In
International Journal of Radiation Oncology, Biology, Physics
Volume
105
Published Date
Start Page
E102
End Page
E102
DOI
10.1016/j.ijrobp.2019.06.2296

First in Human Clinical Trial of a Metalloporphyrin Dual Radioprotectant and Radiosensitizer, BMX-001, in Newly Diagnosed High-Grade Glioma Undergoing Concurrent Chemoradiation

Authors
Peters, KB; Kirkpatrick, JP; Batinic-Haberle, I; Affronti, ML; Woodring, S; Iden, D; Lipp, ES; Boyd, K; Healy, P; Herndon, J; Spasojevic, I; Penchev, S; Gad, S; Silberstein, D; Johnson, MO; Randazzo, D; Desjardins, A; Friedman, HS; Ashley, DM; Crapo, J
MLA Citation
Peters, K. B., et al. “First in Human Clinical Trial of a Metalloporphyrin Dual Radioprotectant and Radiosensitizer, BMX-001, in Newly Diagnosed High-Grade Glioma Undergoing Concurrent Chemoradiation.” International Journal of Radiation Oncology*Biology*Physics, vol. 105, no. 1, Elsevier BV, 2019, pp. E106–E106. Crossref, doi:10.1016/j.ijrobp.2019.06.2305.
URI
https://scholars.duke.edu/individual/pub1415097
Source
crossref
Published In
International Journal of Radiation Oncology, Biology, Physics
Volume
105
Published Date
Start Page
E106
End Page
E106
DOI
10.1016/j.ijrobp.2019.06.2305

A randomized phase II trial of veliparib (V), radiotherapy (RT) and temozolomide (TMZ) in patients (pts) with unmethylated MGMT (uMGMT) glioblastoma (GBM).

Authors
Khasraw, M; McDonald, KL; Rosenthal, M; Lwin, Z; Ashley, DM; Wheeler, H; Barnes, E; Foote, MC; Koh, E-S; Sulman, EP; Back, M; Buckland, M; Sim, H-W; Fisher, L; Leonard, R; Hall, M; Yip, S; Simes, J
MLA Citation
Khasraw, Mustafa, et al. “A randomized phase II trial of veliparib (V), radiotherapy (RT) and temozolomide (TMZ) in patients (pts) with unmethylated MGMT (uMGMT) glioblastoma (GBM)..” Journal of Clinical Oncology, vol. 37, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2019, pp. 2011–2011. Crossref, doi:10.1200/jco.2019.37.15_suppl.2011.
URI
https://scholars.duke.edu/individual/pub1415252
Source
crossref
Published In
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Volume
37
Published Date
Start Page
2011
End Page
2011
DOI
10.1200/jco.2019.37.15_suppl.2011